Zacks: Analysts Anticipate Eyegate Pharmaceuticals Inc (EYEG) Will Announce Earnings of -$0.26 Per Share

Analysts expect that Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) will announce earnings of ($0.26) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Eyegate Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.28) and the highest is ($0.24). Eyegate Pharmaceuticals reported earnings per share of ($0.38) during the same quarter last year, which suggests a positive year over year growth rate of 31.6%. The company is expected to issue its next earnings results on Thursday, February 22nd.

According to Zacks, analysts expect that Eyegate Pharmaceuticals will report full year earnings of ($1.05) per share for the current fiscal year, with EPS estimates ranging from ($1.17) to ($0.97). For the next fiscal year, analysts forecast that the company will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.74) to ($0.61). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Eyegate Pharmaceuticals.

Separately, HC Wainwright set a $5.00 target price on shares of Eyegate Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 19th.

Shares of Eyegate Pharmaceuticals (EYEG) traded up $0.02 during mid-day trading on Friday, hitting $1.19. 131,146 shares of the company traded hands, compared to its average volume of 437,757. The company has a market cap of $20.99, a P/E ratio of -1.01 and a beta of 3.19. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01. Eyegate Pharmaceuticals has a 1-year low of $0.90 and a 1-year high of $3.90.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. raised its holdings in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the period. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent quarter. Institutional investors own 11.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)

What are top analysts saying about Eyegate Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eyegate Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit